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Perhaps more than any other malignancy, systemic therapy for metastatic prostate cancer has 
focused on a single oncogenic target:  the androgen receptor (AR).  Dramatic regressions following 
castration occur in the vast majority of patients, first demonstrated in the seminal work of Charles 
Huggins in 1941 [Huggins 1941].  Even in the castration resistant setting, the cancer remains 
androgen driven in most patients [Ang 2009], a concept that has been unequivocally proven by the 
clinical success of abiraterone acetate, and enzalutamide.  Even docetaxel, a broad spectrum 
antineoplastic, is thought to exert at least part of its effect against prostate cancer through 
preventing microtubule dependent translocation of the AR from the cytoplasm to the nucleus 
[Thadani-Mulero 2012].  Yet despite successes in targeting the AR, resistance invariably develops 
to these agents, with recent evidence suggesting this is due in at least some cases, maddeningly, to 
ongoing activity of the AR [Buttigliero 2015].  Indeed the fact that resistance and disease 
progression are frequently heralded by a rising PSA indicate ongoing activity of the AR.  Hence, 
interest in targeting this pathway remains. 
 
Recently a number of novel therapies that either directly or indirectly target the AR have been 
developed with purported theoretical advantages over abiraterone or enzalutamide: orteronel and 
VT464 offer more selective inhibition of CYP17 C17,20-lyase with less effect on 17α-hydroxylase 
compared to abiraterone, potentially decreasing mineralocorticoid toxicity, with VT-464 not 
requiring steroid co-administration; galeterone acts as a dual inhibitor of C17,20-lyase and AR 
antagonist, and also doesn’t require steroid co-administration; and ARN-509, an AR antagonist 
that shows higher potency and lower CNS penetration than enzalutamide.  All of these agents are 
currently undergoing evaluation in clinical trials [Bambury 2015]. 
 
In this month’s issue of European Urology, Massard and colleagues address another addition to 
the field, ODM-201.  Like enzalutamide and ARN-509, it functions as an AR antagonist by 
interacting with the ligand binding C-terminus domain, and prevents nuclear translocation of the 
AR.  However, it has a higher AR binding affinity than either enzalutamide or ARN-509, it is 
active against some forms of mutant AR which enzalutamide and ARN-509 are not, and it does 
not cross the blood brain barrier and as such it is not thought to predispose to seizures [Fizazi 2014; 
Fizazi 2015].  In order to understand the current study, one must be familiar with the clinical 
development of ODM-201.  In brief, the phase I/II ARADES trial [Fizazi 2014] found that doses 
of ODM-201 up to 1800mg daily were well tolerated with no dose-limiting toxicities in patients 
with metastatic CRPC and no maximum tolerated dose identified, with the most common toxicities 
being fatigue, diarrhea, arthalgias, back pain, and headache.  Patients were then randomized to 
receive 200mg, 400mg, or 1400mg of ODM-201 daily, with three different cohorts of patients 
represented in each dose level:  chemotherapy- and CYP17 inhibitor-naive; post chemotherapy 
and CYP17 inhibitor-naive; and post CYP17 inhibitor.  PSA and objective response rates were 
similar across the dose levels, with chemotherapy- and CYP17 inhibitor-naive patients 
unsurprisingly showing the highest response rates.  Based on this data, the randomized phase III 
ARAMIS trial of ODM-201 versus placebo in high-risk non-metastatic CRPC (NCT02200614) 
was planned, with a selected daily dose of 1200mg; however, the aforementioned ARADES trial 
used 100mg capsules, therefore patients in ARAMIS would be required to take an unpalatable 
twelve capsules per day.  Hence the current trial, which evaluated the comparative 
pharmacokinetic profiles of two different 300mg tablets with the original 100mg capsules, 
followed by an extension phase where thirty chemotherapy- and CYP17 inhibitor-naive patients 
were treated with a daily dose 1200mg of ODM-201.   
 
Importantly, this trial showed similar bioavailability between the tablets and capsules when taken 
with food, with a doubling of plasma exposure when either tablet formulation is taken with food 
compared to the fasted state.  Furthermore, this study confirmed the previously demonstrated 
safety profile, with no dose reductions and only grade 1 treatment related adverse events.  In the 
extension phase clear evidence of antitumour activity was seen with with ≥50% PSA declines in 
83%, objective radiographic response in 29% of those evaluable, and a median time to 
radiographic progression of 66 weeks. 
 
This trial serves as an important bridge between the ARADES and the ongoing ARAMIS trials by 
demonstrating equivalency between three different formulations of ODM-201, meaning that 
patients in ARAMIS will thankfully only have to swallow four pills a day instead of twelve, and  
can still expect the same safety and efficacy previously demonstrated with this drug.  While the 
authors highlight that no seizures have been seen is this trial or ARADES despite the inclusion of 
patients with prior or elevated risk of seizure, the small number of patients studied to date prevent 
one from making any firm conclusions about this.  And while the theoretical lower risk of seizure 
is interesting, it is likely of little clinical relevance.  Seizures due to enzalutamide are rare, at least 
in patients without risk factors.  The frequency in patients at risk is currently unknown, but is 
currently being evaluated in an ongoing phase IV trial (NCT01977651).  While it is true that these 
patients are currently precluded from receiving enzalutamide, they can usually be safely treated 
with abiraterone.  Many health jurisdictions only allow an individual to receive one of these agents, 
and indeed current evidence doesn’t support their sequential use [Bianchini 2014; Azad 2015].  
The efficacy analysis done frankly doesn’t add any more information to what has previously been 
demonstrated in ARADES.  While the response rates seen in this trial are impressive, the only 
reliable conclusion that can be drawn is that this drug warrants further evaluation, a conclusion 
that was already made after ARADES.  
 In many ways, the development of ODM-201 highlights the recent successes and future challenges 
for drug development in CRPC.  Prior to the introduction of abiraterone and enzalutamide, the 
response rates seen with ODM-201 would have been considered staggering, but now this kind of 
activity is expected of novel AR targeting drugs.  And while ODM-201 is clearly highly active, it 
is likely to struggle to find regulatory approval, a fact that is highlighted by the example of 
orteronel, another highly active AR targeting drug that failed to demonstrate an OS advantage in 
metastatic CRPC in two large placebo controlled phase III trials, likely due to the availability of 
abiraterone and enzalutamide to patients upon progression [Fizazi 2015, Saad 2015].  Hence the 
developers of ODM-201 appear to have learned from this cautionary tale, and are seeking to 
develop this drug in a space not already filled by abiraterone or enzalutamide, in non-metastatic 
CRPC, and by targeting a primary endpoint, metastases free survival, that will not to be affected 
by post-progression therapies.  With the availability of approved agents with overlapping 
mechanisms of action, it has become extremely difficult to demonstrate an OS advantage.  And 
since there are no accepted surrogate endpoints for OS in CRPC, the bar is now set much higher.  
Thus new agents are now being evaluated either in combination studies, select patient niches, or 
biomarker selected populations, as opposed to traditional placebo controlled trials in unselected 
populations.   While ODM-201 is clearly well tolerated and highly active, whether it will succeed 
in the long, hard climb to regulatory approval remains to be seen. 
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